Clinical Trials Directory

Trials / Conditions / Female Contraception

Female Contraception

24 registered clinical trials studyying Female Contraception — 3 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingA Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception
NCT07222228
Premier ResearchPhase 2
RecruitingEfficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive
NCT06394999
Leiden University Medical CenterPhase 3
CompletedPatient Factors Associated With Fragmentation of Copper Intrauterine Devices Requiring Hysteroscopic Removal
NCT07351084
University of Kansas Medical Center—
RecruitingStudy to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potenti
NCT06672016
Mylan Pharmaceuticals IncPhase 3
Active Not RecruitingA Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contracep
NCT04143659
Premier ResearchPhase 1
CompletedStudy of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring
NCT03432416
Premier ResearchPhase 2
CompletedCompare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard
NCT03124160
FHI 360Phase 3
CompletedDescriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptabili
NCT01833793
Bayer—
UnknownOral Contraceptives and Economic Behaviour
NCT02257671
Karolinska University HospitalN/A
CompletedPrevention of Ovulation Achieved by Single Intra-vaginal Administration of Levogel as Compared to Oral LNG
NCT01286948
Population CouncilPhase 1
CompletedA Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy
NCT01178125
Teva Branded Pharmaceutical Products R&D, Inc.Phase 3
CompletedRelative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORT
NCT00511784
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.—
CompletedBioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) Wit
NCT00709189
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 1
CompletedBioequivalence Study of Patches With Different Equilibration Profiles
NCT00775086
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 1
CompletedA Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Trans
NCT00258063
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 1
CompletedA Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contracept
NCT00258076
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 1
CompletedEvaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patc
NCT00261482
Janssen Pharmaceutica N.V., BelgiumPhase 4
CompletedBioequivalence Study of Patches With Different Release Profiles
NCT00697307
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.—
CompletedAn Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contrace
NCT00653016
Janssen-Ortho Inc., CanadaPhase 4
CompletedA Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Cont
NCT00254865
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 1
CompletedA Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attack
NCT00377988
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.—
CompletedPostmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Ve
NCT00331071
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.—
CompletedA Study of Efficacy and Safety With the Transdermal Contraceptive System.
NCT00236769
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
CompletedA Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.
NCT00236795
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3